Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHEBURANE vs POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pheburane (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This alternative pathway for nitrogen excretion reduces ammonia levels in patients with urea cycle disorders.
Phosphate supplementation to correct hypophosphatemia; acts as a buffer and is essential for cellular energy metabolism (ATP), bone mineralization, and acid-base balance.
Adjunct therapy for nitrogen removal in patients with urea cycle disorders (UCDs) involving deficiencies of carbamyl phosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase,Off-label: Management of hyperammonemia in other conditions
Treatment of hypophosphatemia,Total parenteral nutrition (TPN) additive,Phosphate replacement in patients with phosphate depletion
Adults: 1 gram orally twice daily, increased as tolerated to 2 grams orally twice daily. Maximum dose: 20 grams per day.
IV: 2.5-5 mmol phosphate/kg body weight over 24 hours; typical dose 10-30 mmol phosphate over 4-6 hours; do not exceed 60 mmol phosphate/day.
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged (up to 4-6 hours), necessitating dose adjustment.
Phosphate: 3-4 hours in healthy adults; prolonged with renal impairment. Potassium: short distribution half-life (~1-1.5 hours); no true terminal half-life due to tight regulation.
Primarily hepatic and renal; hydrolyzed by esterases to phenylacetate; phenylacetate then conjugated with glutamine via acyl-Co A synthetase and acyl-Co A:glutamine N-acyltransferase to form phenylacetylglutamine.
Phosphate is freely filtered by the glomerulus and reabsorbed in the proximal tubule; excess is excreted renally. No significant hepatic metabolism.
Primarily renal excretion. Approximately 50-80% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion. Biliary/fecal elimination is minimal (<5%).
Renal: >90% of phosphate is reabsorbed or excreted by the kidneys; potassium is primarily excreted renally. Fecal elimination accounts for <10% of total phosphate loss.
Approximately 10-20% bound to plasma proteins, primarily albumin. Binding is low and not clinically significant.
Phosphate: 10-15% bound to serum proteins (albumin and immunoglobulins). Potassium: <5% protein bound.
Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid. Not extensively distributed into tissues.
Phosphate: 0.15-0.3 L/kg (primarily extracellular fluid). Potassium: 0.5-0.7 L/kg (distributes into intracellular space).
Oral bioavailability is approximately 80-100% after administration of the sodium phenylbutyrate prodrug. PHEBURANE itself is a prodrug; bioavailability refers to conversion to phenylacetate and then to phenylacetylglutamine.
Intravenous: 100% bioavailability. Oral (not applicable for this formulation): 60-70% for phosphate salts; potassium salts >90%.
Contraindicated in patients with GFR < 50 m L/min/1.73 m² due to risk of hyperammonemia.
GFR <30 m L/min: initiate at 50% of standard dose and titrate based on serum phosphate and potassium levels; avoid if GFR <15 m L/min unless severe hypophosphatemia.
No specific adjustment recommended for Child-Pugh A or B. Use with caution in severe hepatic impairment (Child-Pugh C) due to limited data.
No specific Child-Pugh based recommendations; use with caution in severe hepatic impairment due to potential for electrolyte disturbances.
Neonates and children: 4.5 to 5.9 grams/m²/day orally in 2 to 4 divided doses. Doses up to 12.5 grams/day have been used.
IV: 0.5-1 mmol phosphate/kg over 12-24 hours; monitor serum phosphate and potassium closely; do not exceed 5 mmol/kg/day.
No specific adjustments recommended; use with caution due to age-related renal decline. Monitor renal function and ammonia levels.
Initiate at lower end of dosing range; monitor renal function and serum electrolytes more frequently due to age-related decline in GFR.
None
None
May cause fluid retention and electrolyte abnormalities (e.g., hypernatremia, hypokalemia) due to sodium content,Pancreatitis has been reported,Neurotoxicity with high plasma phenylacetate levels (e.g., somnolence, confusion, seizures),May impair platelet function; caution in bleeding disorders or surgery,Monitor ammonia levels, serum electrolytes, liver function, and complete blood counts regularly
Hyperphosphatemia, especially in renal impairment,Hypocalcemia due to precipitation with calcium,Monitor serum calcium, phosphate, and renal function,Avoid extravasation (may cause tissue necrosis),Not for IV push; give as slow infusion
Hypersensitivity to sodium phenylbutyrate or any component of the formulation,Patients in whom adequate nitrogen removal cannot be achieved or who are not suitable for alternative therapy (e.g., hemodialysis)
Hyperphosphatemia,Hypocalcemia,Renal failure (unless on dialysis),Patients with known hypersensitivity to any component
Avoid high-protein foods as they increase ammonia production. Take with meals to improve tolerability. No known significant food-drug interactions.
Avoid high-phosphate foods (e.g., dairy, nuts, seeds, whole grains, cola) and high-potassium foods (e.g., bananas, oranges, potatoes, spinach) unless prescribed. Limit intake of calcium-rich foods if calcium levels are low.
Pheburance (sodium phenylbutyrate) has not been studied in pregnant women. In animal studies, phenylbutyrate caused fetal harm at doses equivalent to human therapeutic doses. First trimester: Potential for teratogenicity based on animal data. Second and third trimesters: May cause fetal growth restriction and neurotoxicity due to ammonia-lowering effects. Use only if benefit outweighs risk.
FDA Pregnancy Category C. No adequate studies in pregnant women. First trimester: risk cannot be ruled out; use only if clearly needed. Second/third trimesters: may cause hypocalcemia, electrolyte imbalances in fetus; avoid prolonged use.
It is unknown if sodium phenylbutyrate or its metabolites are excreted in human milk. The M/P ratio has not been established. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy.
Excretion in human milk unknown; M/P ratio not determined. Use with caution, weighing benefit against potential risk of electrolyte disturbances in the nursing infant.
Pregnancy may alter pharmacokinetics of sodium phenylbutyrate due to increased plasma volume, renal clearance, and hepatic metabolism. Although specific dose adjustment recommendations are lacking, consider monitoring ammonia levels closely and titrating dose to maintain therapeutic ammonia control. Dose may need to be increased in late pregnancy and postpartum. Start at the lowest effective dose.
Increased plasma volume may require higher doses to achieve therapeutic levels; monitor serum electrolytes closely to avoid hyperphosphatemia or hypocalcemia. No standard dose adjustment established.
PHEBURANE (sodium phenylbutyrate) is used as adjunctive therapy for urea cycle disorders. Monitor plasma ammonia, arginine, and glutamine levels. Avoid in patients with severe hepatic impairment. Discontinue if hyperammonemic encephalopathy occurs.
Do not administer undiluted; must be infused via central line if concentration > 0.45% potassium phosphate. Monitor serum potassium, phosphate, calcium, and magnesium. Rate of infusion should not exceed 10 mmol/h of phosphate. Risk of hypocalcemia due to phosphate precipitation. Use with caution in renal impairment.
Take with food or milk to reduce gastrointestinal irritation.,Do not crush or chew tablets; swallow whole.,Report any signs of hyperammonemia (e.g., lethargy, vomiting, confusion) immediately.,Maintain a low-protein diet as prescribed.,Store at room temperature away from moisture and heat.
This medication is given through a vein to restore phosphate and potassium levels.,Report any signs of infusion site pain, redness, or swelling.,Inform your healthcare provider if you experience muscle cramps, weakness, numbness, or tingling.,This medication may cause low calcium levels; report symptoms such as muscle spasms or confusion.,Do not consume additional potassium or phosphate supplements unless directed by your doctor.
No interactions on record
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHEBURANE vs POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE, answered by our medical review team.
PHEBURANE is a Ammonia Detoxicant that works by Pheburane (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This alternative pathway for nitrogen excretion reduces ammonia levels in patients with urea cycle disorders.. POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE is a Electrolyte that works by Phosphate supplementation to correct hypophosphatemia; acts as a buffer and is essential for cellular energy metabolism (ATP), bone mineralization, and acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHEBURANE and POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHEBURANE is: Adults: 1 gram orally twice daily, increased as tolerated to 2 grams orally twice daily. Maximum dose: 20 grams per day.. The standard adult dose of POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE is: IV: 2.5-5 mmol phosphate/kg body weight over 24 hours; typical dose 10-30 mmol phosphate over 4-6 hours; do not exceed 60 mmol phosphate/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHEBURANE and POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHEBURANE is classified as Category C. Pheburance (sodium phenylbutyrate) has not been studied in pregnant women. In animal studies, phenylbutyrate caused fetal harm at doses equivalent to human therapeutic doses. First. POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE is classified as Category A/B. FDA Pregnancy Category C. No adequate studies in pregnant women. First trimester: risk cannot be ruled out; use only if clearly needed. Second/third trimesters: may cause hypocalce. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.